Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 37.31
(-0.8%)
USD 37.31
(-0.8%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -353.73 Million USD | 13.93% |
| 2022 | -411 Million USD | -1270.0% |
| 2021 | -30 Million USD | 82.56% |
| 2020 | -172 Million USD | -146.99% |
| 2019 | 366 Million USD | 696.36% |
| 2018 | -61.37 Million USD | -350.15% |
| 2017 | 24.53 Million USD | 152.97% |
| 2016 | -46.31 Million USD | 38.87% |
| 2015 | -75.76 Million USD | -58.73% |
| 2014 | -47.73 Million USD | 7.62% |
| 2013 | -51.66 Million USD | 25.04% |
| 2012 | -68.92 Million USD | 3.06% |
| 2011 | -71.1 Million USD | -47.03% |
| 2010 | -48.35 Million USD | -75.6% |
| 2009 | -27.53 Million USD | -110.86% |
| 2008 | -13.06 Million USD | 66.47% |
| 2007 | -38.94 Million USD | 42.82% |
| 2006 | -68.11 Million USD | -19.12% |
| 2005 | -57.18 Million USD | 51.48% |
| 2004 | -117.85 Million USD | -49.22% |
| 2003 | -78.97 Million USD | -55.43% |
| 2002 | -50.81 Million USD | -10.22% |
| 2001 | -46.1 Million USD | -59.03% |
| 2000 | -28.99 Million USD | 32.74% |
| 1999 | -43.1 Million USD | -32.62% |
| 1998 | -32.5 Million USD | -3.17% |
| 1997 | -31.5 Million USD | -7.51% |
| 1996 | -29.3 Million USD | -14.45% |
| 1995 | -25.6 Million USD | -13.78% |
| 1994 | -22.5 Million USD | -22.95% |
| 1993 | -18.3 Million USD | 15.28% |
| 1992 | -21.6 Million USD | -105.71% |
| 1991 | -10.5 Million USD | -133.33% |
| 1990 | -4.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -149.51 Million USD | -2341.83% |
| 2024 Q2 | -66.09 Million USD | 55.8% |
| 2023 Q3 | -143 Million USD | -57.14% |
| 2023 Q4 | -6.12 Million USD | 95.72% |
| 2023 FY | -353.73 Million USD | 13.93% |
| 2023 Q1 | -114 Million USD | 45.19% |
| 2023 Q2 | -91 Million USD | 20.18% |
| 2022 Q1 | -57.47 Million USD | -126.01% |
| 2022 Q2 | -85.51 Million USD | -48.78% |
| 2022 Q3 | -59.13 Million USD | 30.84% |
| 2022 Q4 | -208 Million USD | -251.72% |
| 2022 FY | -411 Million USD | -1270.0% |
| 2021 FY | -30 Million USD | 82.56% |
| 2021 Q1 | -91.97 Million USD | -299.87% |
| 2021 Q2 | -72.96 Million USD | 20.66% |
| 2021 Q4 | 221 Million USD | 357.43% |
| 2021 Q3 | -85.84 Million USD | -17.65% |
| 2020 Q1 | -61.12 Million USD | -123.42% |
| 2020 FY | -172 Million USD | -146.99% |
| 2020 Q2 | -51.75 Million USD | 15.33% |
| 2020 Q3 | -36.53 Million USD | 29.4% |
| 2020 Q4 | -23 Million USD | 37.05% |
| 2019 FY | 366 Million USD | 696.36% |
| 2019 Q1 | 121.53 Million USD | 1027.2% |
| 2019 Q3 | 2.52 Million USD | 113.28% |
| 2019 Q2 | -19 Million USD | -115.63% |
| 2019 Q4 | 261 Million USD | 10244.83% |
| 2018 Q2 | -50.28 Million USD | -1423.21% |
| 2018 Q4 | 10.78 Million USD | 158.06% |
| 2018 FY | -61.37 Million USD | -350.15% |
| 2018 Q3 | -18.57 Million USD | 63.06% |
| 2018 Q1 | -3.3 Million USD | -94.98% |
| 2017 FY | 24.53 Million USD | 152.97% |
| 2017 Q1 | 13.98 Million USD | -66.01% |
| 2017 Q4 | -1.69 Million USD | -112.17% |
| 2017 Q3 | 13.9 Million USD | 932.38% |
| 2017 Q2 | -1.67 Million USD | -111.95% |
| 2016 Q4 | 41.15 Million USD | 155.49% |
| 2016 Q2 | -48.92 Million USD | 10.48% |
| 2016 Q3 | 16.1 Million USD | 132.92% |
| 2016 FY | -46.31 Million USD | 38.87% |
| 2016 Q1 | -54.65 Million USD | 13.17% |
| 2015 Q4 | -62.94 Million USD | -30.75% |
| 2015 Q1 | -9.33 Million USD | -192.56% |
| 2015 Q2 | 44.64 Million USD | 578.52% |
| 2015 Q3 | -48.13 Million USD | -207.82% |
| 2015 FY | -75.76 Million USD | -58.73% |
| 2014 Q2 | -6.65 Million USD | 77.58% |
| 2014 FY | -47.73 Million USD | 7.62% |
| 2014 Q4 | 10.08 Million USD | 146.9% |
| 2014 Q1 | -29.66 Million USD | -49.4% |
| 2014 Q3 | -21.49 Million USD | -223.2% |
| 2013 Q3 | -25.5 Million USD | -221.71% |
| 2013 FY | -51.66 Million USD | 25.04% |
| 2013 Q4 | -19.85 Million USD | 22.14% |
| 2013 Q2 | -7.92 Million USD | -587.88% |
| 2013 Q1 | 1.62 Million USD | 106.22% |
| 2012 Q3 | -28.04 Million USD | -858.82% |
| 2012 Q1 | -18.45 Million USD | 0.86% |
| 2012 Q4 | -26.11 Million USD | 6.87% |
| 2012 FY | -68.92 Million USD | 3.06% |
| 2012 Q2 | 3.69 Million USD | 120.03% |
| 2011 Q4 | -18.61 Million USD | 16.58% |
| 2011 FY | -71.1 Million USD | -47.03% |
| 2011 Q1 | -16.1 Million USD | -1.58% |
| 2011 Q2 | -14.06 Million USD | 12.71% |
| 2011 Q3 | -22.31 Million USD | -58.72% |
| 2010 FY | -48.35 Million USD | -75.6% |
| 2010 Q4 | -15.85 Million USD | -77.24% |
| 2010 Q2 | -18.67 Million USD | -282.62% |
| 2010 Q1 | -4.88 Million USD | 58.19% |
| 2010 Q3 | -8.94 Million USD | 52.08% |
| 2009 FY | -27.53 Million USD | -110.86% |
| 2009 Q3 | -10.39 Million USD | -115.37% |
| 2009 Q2 | -4.82 Million USD | -651.87% |
| 2009 Q4 | -11.67 Million USD | -12.26% |
| 2009 Q1 | -642 Thousand USD | -119.89% |
| 2008 Q2 | -3.13 Million USD | 64.52% |
| 2008 Q4 | 3.22 Million USD | 174.65% |
| 2008 FY | -13.06 Million USD | 66.47% |
| 2008 Q1 | -8.83 Million USD | -4.6% |
| 2008 Q3 | -4.32 Million USD | -38.01% |
| 2007 Q3 | 10.05 Million USD | 151.15% |
| 2007 FY | -38.94 Million USD | 42.82% |
| 2007 Q1 | -20.9 Million USD | -24.89% |
| 2007 Q2 | -19.66 Million USD | 5.94% |
| 2007 Q4 | -8.44 Million USD | -183.95% |
| 2006 FY | -68.11 Million USD | -19.12% |
| 2006 Q4 | -16.73 Million USD | 8.37% |
| 2006 Q3 | -18.26 Million USD | -6.79% |
| 2006 Q2 | -17.1 Million USD | -6.78% |
| 2006 Q1 | -16.01 Million USD | -86.06% |
| 2005 Q3 | -12.14 Million USD | 6.03% |
| 2005 Q4 | -8.6 Million USD | 29.12% |
| 2005 Q2 | -12.92 Million USD | 45.02% |
| 2005 FY | -57.18 Million USD | 51.48% |
| 2005 Q1 | -23.5 Million USD | 54.62% |
| 2004 FY | -117.85 Million USD | -49.22% |
| 2004 Q1 | -22.33 Million USD | -3.98% |
| 2004 Q2 | -21.34 Million USD | 4.45% |
| 2004 Q3 | -22.38 Million USD | -4.87% |
| 2004 Q4 | -51.79 Million USD | -131.45% |
| 2003 Q4 | -21.48 Million USD | -12.66% |
| 2003 Q2 | -19.52 Million USD | -3.21% |
| 2003 FY | -78.97 Million USD | -55.43% |
| 2003 Q1 | -18.91 Million USD | -68.17% |
| 2003 Q3 | -19.06 Million USD | 2.32% |
| 2002 Q1 | -9.71 Million USD | -26.26% |
| 2002 Q4 | -11.24 Million USD | 35.77% |
| 2002 Q3 | -17.5 Million USD | -41.9% |
| 2002 Q2 | -12.33 Million USD | -26.97% |
| 2002 FY | -50.81 Million USD | -10.22% |
| 2001 FY | -46.1 Million USD | -59.03% |
| 2001 Q1 | -17.23 Million USD | -72.13% |
| 2001 Q4 | -7.69 Million USD | -63.52% |
| 2001 Q3 | -4.7 Million USD | 71.41% |
| 2001 Q2 | -16.46 Million USD | 4.47% |
| 2000 Q4 | -10.01 Million USD | -4960.19% |
| 2000 Q1 | -11 Million USD | 11.93% |
| 2000 Q3 | 206 Thousand USD | 102.52% |
| 2000 Q2 | -8.17 Million USD | 25.74% |
| 2000 FY | -28.99 Million USD | 32.74% |
| 1999 Q3 | -8.1 Million USD | 32.5% |
| 1999 FY | -43.1 Million USD | -32.62% |
| 1999 Q4 | -12.5 Million USD | -54.32% |
| 1999 Q1 | -10.5 Million USD | -7.14% |
| 1999 Q2 | -12 Million USD | -14.29% |
| 1998 Q3 | 1 Million USD | 107.69% |
| 1998 Q4 | -9.8 Million USD | -1080.0% |
| 1998 Q2 | -13 Million USD | -18.18% |
| 1998 Q1 | -11 Million USD | -4.76% |
| 1998 FY | -32.5 Million USD | -3.17% |
| 1997 FY | -31.5 Million USD | -7.51% |
| 1997 Q2 | -9.7 Million USD | -8.99% |
| 1997 Q3 | -2.6 Million USD | 73.2% |
| 1997 Q1 | -8.9 Million USD | 8.25% |
| 1997 Q4 | -10.5 Million USD | -303.85% |
| 1996 Q4 | -9.7 Million USD | -44.78% |
| 1996 Q1 | -4.8 Million USD | 22.58% |
| 1996 FY | -29.3 Million USD | -14.45% |
| 1996 Q3 | -6.7 Million USD | 17.28% |
| 1996 Q2 | -8.1 Million USD | -68.75% |
| 1995 Q3 | -7.4 Million USD | -23.33% |
| 1995 Q4 | -6.2 Million USD | 16.22% |
| 1995 FY | -25.6 Million USD | -13.78% |
| 1995 Q2 | -6 Million USD | 1.64% |
| 1995 Q1 | -6.1 Million USD | 45.54% |
| 1994 Q2 | -4.8 Million USD | -6.67% |
| 1994 Q3 | -5 Million USD | -4.17% |
| 1994 Q4 | -11.2 Million USD | -124.0% |
| 1994 FY | -22.5 Million USD | -22.95% |
| 1994 Q1 | -4.5 Million USD | -2.27% |
| 1993 Q2 | -4.6 Million USD | 9.8% |
| 1993 Q4 | -4.4 Million USD | 0.0% |
| 1993 FY | -18.3 Million USD | 15.28% |
| 1993 Q1 | -5.1 Million USD | 31.08% |
| 1993 Q3 | -4.4 Million USD | 4.35% |
| 1992 FY | -21.6 Million USD | -105.71% |
| 1992 Q2 | -4.2 Million USD | 16.0% |
| 1992 Q1 | -5 Million USD | 0.0% |
| 1992 Q3 | -4.9 Million USD | -16.67% |
| 1992 Q4 | -7.4 Million USD | -51.02% |
| 1991 Q2 | -2.3 Million USD | -76.92% |
| 1991 Q3 | -2.4 Million USD | -4.35% |
| 1991 Q4 | -5 Million USD | -108.33% |
| 1991 FY | -10.5 Million USD | -133.33% |
| 1991 Q1 | -1.3 Million USD | 78.33% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | -6 Million USD | -1300.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | -4.5 Million USD | 0.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -109.084% |
| Dynavax Technologies Corporation | -37.02 Million USD | -855.304% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -6613.418% |
| Perrigo Company plc | 151.9 Million USD | 332.87% |
| Illumina, Inc. | -1.06 Billion USD | 66.91% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 105.157% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 23.196% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 97.487% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 117.892% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -219.785% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 108.74% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -691.927% |
| Waters Corporation | 817.67 Million USD | 143.26% |
| Biogen Inc. | 1.29 Billion USD | 127.277% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -29.096% |
| Evolus, Inc. | -49.23 Million USD | -618.482% |
| Adicet Bio, Inc. | -152.03 Million USD | -132.659% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -191.148% |
| bluebird bio, Inc. | -244.26 Million USD | -44.816% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -127.387% |
| FibroGen, Inc. | -281.81 Million USD | -25.519% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 126.202% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -684.719% |
| Homology Medicines, Inc. | -48.25 Million USD | -633.043% |
| Geron Corporation | -193.94 Million USD | -82.388% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -25.358% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -381.305% |
| Myriad Genetics, Inc. | -123.7 Million USD | -185.958% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -250.829% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 31.353% |
| Zoetis Inc. | 3.06 Billion USD | 111.526% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -633.88% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 132.533% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 281.922% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 108.212% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -803.456% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -28.16% |
| Verastem, Inc. | -92.08 Million USD | -284.138% |
| Nektar Therapeutics | -137.42 Million USD | -157.399% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -52.585% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -263.333% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -32.076% |
| OPKO Health, Inc. | -157.02 Million USD | -125.276% |
| Exelixis, Inc. | 170.88 Million USD | 306.999% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 240.984% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 429.72% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -534.425% |
| uniQure N.V. | -282.87 Million USD | -25.05% |
| Imunon, Inc. | -21.03 Million USD | -1581.991% |
| Blueprint Medicines Corporation | -486.27 Million USD | 27.258% |
| Insmed Incorporated | -709.62 Million USD | 50.153% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 204.786% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 9.645% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1814.39% |
| Incyte Corporation | 620.52 Million USD | 157.005% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 51.304% |